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Abstract
Epidemiological data show that the consumption of 
added sugars as ingredients in processed or prepared 
foods and caloric beverages has dramatically increased. 
Fructose and fructose-based sweeteners are the most 
commonly added sugars and high-fructose corn syrup 
(HFCS-55: 55% fructose, 42% glucose and 3% higher 
saccharides) accounts for over 40% of all added caloric 
sweeteners. Concerns regarding the health risk of added 
sugar follow the demonstration that the consumption of 
foods and beverages high in sugars is associated with an 
increased prevalence of obesity, insulin resistance, dys- 
lipidemia and, more recently, ischemic heart and kidney 
diseases. The molecular mechanism(s) underlying the 
detrimental effects of sugar are not completely under- 
stood and their elucidation is critical to provide new 
insights on the health risk of fructose-based sweeteners. 
A better understanding of the key role of fructose over- 
consumption in the development of metabolic disorders 
may contribute to planning new strategies for preventing 
deleterious dietary behaviors from becoming established 
and, thus, curbing the rise in the number of insulin-resis- 
tant, obese and diabetic populations worldwide.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The consumption of  large amounts of  added sugars, a pro- 
minent source of  low nutrient calories used as ingredients 
in processed or prepared foods and caloric beverages (i.e., 
soft-drinks, colas) is a relatively new phenomenon. It was 
not until the mid-19th century that these sweeteners beca- 
me widely available and consumption began to increase 
dramatically[1]. Today, one of  the most commonly consum- 
ed added sugars is high-fructose corn syrup (HFCS-55). 
Normal sugar, known as saccharose, contains equimolar 
quantities of  fructose and glucose whereas HFCS-55 syrup, 
synthesized by refining corn starch, contains 55% fructose 
and 41% glucose. HFCS-55 appeared in 1977, opening a 
new frontier for the sweetener and soft drink industries. In 
the USA where more accurate data are available, HFCS-55 
accounts for the 42% of  total consumption versus 16% in 
1977-1978 and soft drinks account for over 70% of  this 
intake[2]. Bray et al[3] noted that the average intake of  
HFCS-55 (the sole sweetener in US soft drinks) rose 
1000% between 1970 and 1990. In other parts of  the 
world, the problem has been less investigated than in the 
USA. According to a recent survey on over 3300 subjects[4], 
in Italy the mean daily consumption of  soft drinks is 132 
g/d in female teenagers, 203 g/d in male teenagers (10 to 
17.9 years), 114 g/d in adult women and 147 g/d in adult 
men (18 to 64.9 years). It has been recently confirmed 
that the consumption of  foods and beverage with a high 
content in added sugars, mainly fructose, is associated 
with insulin resistance, dyslipidemia and an increased rate 
in obesity[5-7]. In addition to effects on weight, soft drinks 
have been demonstrated to displace essential nutrients 
and contribute to overall poorer diets. Several cross-sec- 
tional studies have shown that increased soft drink intake is 
Online Submissions: http://www.wjgnet.com/1948-9358office
wjd@wjgnet.com
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related to lower consumption of  milk and calcium, althou- 
gh the average effect sizes were small[8-10]. Soft drink con- 
sumption was also related to higher intake of  carbohy- 
drates, lower intakes of  fruit and dietary fiber and lower 
intakes of  a variety of  macronutrients in cross-sectional, 
longitudinal and longer-term experimental studies[11-13]. The 
main diet issues involve a general lack of  education and/or 
understanding of  the implications with recent consum- 
ption patterns. Despite education programs to prevent 
obesity and diabetes worldwide, there has been little focus 
on the reduction of  fructose and HFCS-55 in beverages. 
FRUCTOSE METABOLISM
Fructose is readily absorbed and rapidly metabolized by 
human liver. Fructose enters the cells predominantly throu- 
gh the transporters GLUT5 and/or GLUT2[14]. GLUT2 
has high affinity for glucose and a moderate affinity for 
fructose, whereas GLUT5 predominantly transports fruc- 
tose with very low affinity for glucose. GLUT5 is essential 
for the absorption of  fructose in the intestine and its ex- 
pression is increased in rats or mice fed a fructose-enri- 
ched diet[15]. Both transporters are expressed in the liver, 
the primary site for fructose metabolism. In the liver, fru- 
ctose undergoes a specific metabolism which differs mar- 
kedly from that of  glucose. Fructose is phosphorylated by 
fructokinase (ketohexokinase) to yield fructose-1-phos- 
phate which is then cleaved by aldolase B to glyceraldehyde 
and dihydroxyacetone phosphate which directly forms 
methylglioxale[16]. Fructose can also be phosphorylated by 
hexokinase but the Km for fructose is much higher than 
for glucose which minimizes fructose phosphorylation 
through this pathway. Unlike hexokinase, the fructokinase 
pathway of  fructose metabolism bypasses tightly regulated 
glycolytic checkpoints, especially phosphofructokinase. 
Thus, while glucose metabolism is negatively regulated by 
phosphofructokinase, fructose can continuously enter the 
glycolytic pathway. Therefore, fructose can uncontrollably 
produce glucose, glycogen, lactate and pyruvate, providing 
both the glycerol and acyl portions of  acyl-glycerol mole- 
cules. These particular substrates and the resultant excess 
energy flux due to unregulated fructose metabolism will 
promote the over-production of  triglycerides. 
Another unique characteristic of  fructose metabolism 
is the ability to raise uric acid levels. As fructokinase has 
no negative feedback, all fructose entering the cell is 
rapidly phosphorylated which can result in ATP depletion 
which has been well documented in vitro and in vivo in 
animal models and humans. ATP depletion activates 
enzymes of  purine metabolism which degrade adenine 
nucleotides to uric acid via xanthine oxidoreductase with 
the development of  hyperuricemia[17].
CLINICAL CONSEQUENCES OF HIGH 
DIETARY FRUCTOSE CONSUMPTION
Excessive intake of  fructose, primarily in the form of  
added dietary sugars, has been linked epidemiologically 
with the development of  metabolic syndrome, a cluster of  
clinical and biochemical features that includes abdominal 
obesity, insulin resistance, hypertension and dyslipidemia. 
It is well documented that the administration of  fructose 
to humans induces all of  the features of  metabolic syn- 
drome. A ten week trial of  32 overweight or obese indivi- 
duals from 42 to 70 years demonstrated that plasma lipid 
and lipoprotein concentrations increased markedly during 
fructose consumption and were unchanged in subjects 
consuming glucose[18]. In addition, subjects consuming fru- 
ctose developed visceral obesity (measured by computed 
tomography scan) and insulin resistance. Interestingly, fas- 
ting plasma glucose and insulin levels increased and insulin 
sensitivity decreased in subjects consuming fructose-swee- 
tened beverages but not in those consuming glucose. Re- 
cently Le et al[19] reported that just one week of  a high-fruc- 
tose diet increased ectopic fat deposition in the liver and 
skeletal muscle in healthy young men without a family his- 
tory of  diabetes. Interestingly, healthy normal-weight 
offspring of  patients with type 2 diabetes who are prone to 
develop metabolic disorders have a higher accumulation of  
intrahepatocellular lipids and VLDL-triacylglycerols, thus 
suggesting that they may be more susceptible to the deve- 
lopment of  dyslipidemia and related metabolic disorders 
when consuming significant amounts of  fructose. A recent 
analysis of  liver biopsies combined with survey answers 
from more than 400 people found a link between daily 
fructose consumption and increased hepatic inflammation 
and fibrosis[20]. A statistically significant correlation be- 
tween caloric sweeteners, mainly HFCS-55, and blood lipid 
levels has been also assessed in a cross-sectional study 
among over 6000 US adults from the National Health and 
Nutrition Examination Survey[5]. Fructose ingestion has 
also been associated with higher blood pressure levels in 
both adolescents and adults with no previous history of  
hypertension[21-23].
A clinical study performed in young, healthy male 
volunteers found that ingestion of  3 g of  fructose per kilo- 
gram of  body weight per day (as a 20% fructose solution 
for 6 d) led to a substantial increase in plasma triglycerides 
and an impaired insulin-induced suppression of  adipose 
tissue lipolysis[24]. Furthermore, a positive correlation was 
observed between plasma triglyceride concentration and 
hepatic de novo lipogenesis. These observations support 
the hypothesis that fructose-induced stimulation of  hepa- 
tic de novo lipogenesis is indeed instrumental in increasing 
plasma triglycerides[24]. In a crossover study, Hallfrisch et 
al[25] fed 12 hyperinsulinemic men and 12 male controls 
with diets containing 0%, 7.5% and 15% of  energy from 
fructose for 5 wk each. Total plasma cholesterol and low- 
density lipoprotein cholesterol concentrations were higher 
when the men consumed 7.5% or 15% of  energy as fru- 
ctose compared with starch. Plasma triacylglycerol concen- 
trations in the hyperinsulinemic men increased as the 
amount of  fructose increased.
TOWARDS MECHANISTIC INSIGHTS
Although detrimental effects of  fructose have been estab- 
lished, the mechanisms whereby this happens are only now 
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being discovered. There is some experimental evidence that 
fructose enhances the production of  tumor necrosis factor 
(TNF)-α[26,27], a potent pro-inflammatory cytokine that 
has been demonstrated to induce insulin resistance and 
lipoprotein production. Fructose may also evoke alteration 
of  post-receptor insulin signaling. In skeletal muscle of  ro- 
dents, a high-fructose diet decreased insulin receptor acti- 
vation and the phosphorylation of  insulin receptor substra- 
te-1[28]. Fructose is also known to induce oxidative stress 
and mitochondrial dysfunction, resulting in a stimulation 
of  peroxisome proliferator-activated receptor gamma coa- 
ctivator 1-α and β (PGC1-α and PGC-1β) that drive both 
insulin resistance and lipogenesis[29]. Fructose effects on 
lipogenesis seem to be related to its ability to alter the 
activity of  key lipogenic enzymes and transcription factors 
in the liver, such as pyruvate dehydrogenase kinase and 
sterol-regulatory-element-binding protein-1c (SREBP-1c), 
the principal inducer of  hepatic lipogenesis[30,31]. Fructose 
feeding has been reported to dramatically induce SREBP1c 
expression, compared with feeding with regular chow. This 
effect was largely diminished by treating fructose fed rats 
with PGC1β antisense oligonucleotides[29]. The decrease in 
SREBP1c expression led to decreased induction of  lipo- 
genic enzymes such as fatty acid synthase, which in turn 
accounted for the decreased accumulation of  di- and tria- 
cylglycerol within the livers of  fructose fed rats. This de- 
crease in tissue lipid content was associated with impro- 
vements in insulin action. Another protein involved in the 
regulation of  fructose-mediated lipogenesis is the X-box 
binding protein (XBP)1 which regulates the expression of  
many proteins that are involved in endoplasmic reticulum 
membrane expansion, including the lipogenic enzymes[32]. 
XBP1 protein expression in mice is elevated after fructose 
feeding and is associated with the induction of  critical 
genes involved in fatty acid synthesis[33]. In contrast, dele- 
tion of  XBP1 lowers expression of  SREBP1 and key lipo- 
genic enzymes, decreases rates of  hepatic de novo lipoge- 
nesis and cholesterol synthesis and, in vivo, decreases plasma 
triglyceride concentration and secretion. 
Another important molecular mechanism involved 
in the deleterious effects of  high fructose intake is the 
biochemical process of  non-enzymatic advanced glycation. 
The formation of  advanced glycation end products (AG 
Es), also named Maillard reaction, starts from Schiff  bases 
and the Amadori product, a 1-amino-1-deoxyketose, ob- 
tained by the reaction of  the carbonyl group of  a sugar, 
like glucose, with proteins or lipids amino groups. Glyca- 
tion of  proteins and lipids causes molecular rearrange- 
ments that lead to AGEs. The general mechanisms of  
AGEs effects are: (1) the formation of  cross-links between 
key molecules in the basement membrane of  the extracel- 
lular matrix; (2) the alteration of  intracellular proteins; and 
(3) the interaction of  AGEs with specific receptors on the 
cell surfaces, thus altering intracellular signaling and disrup- 
ting cell function. Although an elevated level of  glucose 
exerts a primary role in the Maillard reaction, glucose has 
a low chemical reactivity in comparison with others sugars 
such as fructose. Recent findings show that fructose pro- 
duces 10 times more AGEs than glucose because the ano- 
merization equilibrium for fructose is shifted more to the 
reactive, open chain form of  the sugar[34]. The in vivo forma- 
tion of  fructose-derived AGEs has long been suspected 
but experimental evidence for their formation and chemi- 
cal characterization are lacking. Several structures of  glu- 
cose-induced protein glycation products have been recently 
identified by mass spectrometry techniques[35]. In contrast, 
the types of  AGEs produced in the presence of  high fruc- 
tose consumption have not yet been structurally clarified.
The mechanism of  fructose-induced hypertension has 
been also extensively investigated, demonstrating the in- 
volvement of  endothelial dysfunction and sympathetic 
activation in hypertension etiology[36,37]. Besides, fructose- 
induced hyperuricemia seems to contribute to the develo- 
pment of  both hypertension and renal injury. Elevated 
uric acid levels have been found to be an independent risk 
factor for hypertension in multiple studies[38]. In an animal 
experimental model of  fructose-induced metabolic syn- 
drome, the reduction in uric acid levels with a xanthine 
oxidase inhibitor resulted in prevention of  systemic and 
glomerular hypertension as well as renal vasoconstriction 
induced by a high fructose diet[39]. Hyperuricemia follow- 
ing high fructose intake was demonstrated to be associ- 
ated with increased oxidative stress, activation of  the 
renin angiotensin system and endothelial dysfunction, 
thus resulting in hypertension[40-42]. Fructose ingestion has 
also been associated with induction of  the potent vaso- 
constrictor endothelin-1 and treatment with the endo- 
thelin receptor antagonist has been demonstrated to pre- 
vent the development of  fructose-induced hypertension 
and decreased plasma Ang Ⅱ levels[43].
CONCLUSION
The controversy that has existed for the last decade regar- 
ding the potential harmfulness of  excess fructose is legiti- 
mate in view of  the dramatic increases in both sweetened 
beverage consumption and the burdens of  obesity and me- 
tabolic syndrome. Most recent findings suggest that high 
fructose intake induces a whole range of  metabolic and car- 
diovascular alterations in both animal and human models. 
Nevertheless, at present there are no objective grounds to 
support that moderate intake of  fructose or of  fructose 
consumed with fruits or honey is unsafe. More extensive 
clinical and experimental studies are needed to provide 
new evidence on the health risk of  fructose-based swee- 
teners. Although AGEs have been suggested to exert a key 
role in the organ damage evoked by fructose-fortified 
diets, the chemical characterization of  the epitope struc- 
tures of  fructose-derived AGEs still needs to be eluci- 
dated by mass spectrometry techniques. Thus, future stu- 
dies on qualitative-quantitative comparison among main 
AGEs deriving from fructose consumption are crucial for a 
better elucidation of  the pathophysiological role of  fruc- 
tose overconsumption. Another unanswered question is 
whether or not fructose can cause hormonal disturbances 
in humans. Currently, results from human studies concern- 
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ing fructose effects on plasma leptin, insulin and adipone- 
ctin are ambiguous and further clinical data are required to 
clarify the potential contribution of  dietary fructose to hor- 
mone dysregulation, of  primary importance in the progres- 
sion of  metabolic syndrome. Similarly, we do not know 
whether there are subgroups of  individuals (obese insulin- 
resistant patients, offspring of  patients with type 2 dia- 
betes) in whom the adverse metabolic effects of  fructose 
may possibly be enhanced. Overall, these investigations 
are crucial for supporting health authorities to define new 
regulations and for planning new strategies to prevent 
deleterious dietary behaviors from becoming established. 
If  widely implemented, these measures may help to cor- 
rect unhealthy dietary habits and to develop new thera- 
peutic approaches to metabolic disorders and the associ- 
ated cardiovascular complications.
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